Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
Modulation Therapeutics, Inc.
Pfizer
National Cancer Institute (NCI)
Mayo Clinic
Stanford University
Alpha-9 Oncology USA Inc.
Fred Hutchinson Cancer Center
Ankyra Therapeutics, Inc
MonTa Biosciences ApS
ViroMissile, Inc.
Pfizer
Tizona Therapeutics, Inc
Werewolf Therapeutics, Inc.
MacroGenics
ModernaTX, Inc.
Adaptimmune
Pierre Fabre Medicament
OncoNano Medicine, Inc.
City of Hope Medical Center
Kezar Life Sciences, Inc.
Memorial Sloan Kettering Cancer Center
AccSalus Biosciences, Inc.
Abramson Cancer Center at Penn Medicine
Incyte Corporation
TuHURA Biosciences, Inc.
St Vincent's Hospital, Sydney
Dana-Farber Cancer Institute
Memgen, Inc.
Pfizer
Leap Therapeutics, Inc.
University of California, San Diego
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Biogen
Scholar Rock, Inc.
National Cancer Institute (NCI)
Altor BioScience
Pfizer
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Pliant Therapeutics, Inc.
Rockefeller University
Eli Lilly and Company